Company Performance - XOMA Royalty reported a quarterly loss of $0.39 per share, better than the Zacks Consensus Estimate of a loss of $0.44, and improved from a loss of $0.60 per share a year ago, representing an earnings surprise of 11.36% [1] - The company posted revenues of $7.2 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 8.06%, and significantly up from $0.83 million in the same quarter last year [2] - Over the last four quarters, XOMA Royalty has exceeded consensus revenue estimates four times, although it has surpassed consensus EPS estimates only once [2] Stock Performance - XOMA Royalty shares have increased approximately 75.5% since the beginning of the year, outperforming the S&P 500's gain of 24.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.49 on revenues of $6.52 million, and for the current fiscal year, it is -$0.12 on revenues of $25.75 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which XOMA Royalty belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Financial Performance - XOMA Royalty reported total income and revenues of $7.2 million for Q3 2024, a significant increase from $0.8 million in Q3 2023[6] - The company recorded a net loss of $17.2 million in Q3 2024, compared to a net loss of $5.5 million in Q3 2023, primarily due to a $14.0 million non-cash impairment charge[12] - Total income and revenues for the three months ended September 30, 2024, were $7,197,000, compared to $830,000 for the same period in 2023, representing a significant increase[18] - The net loss attributable to common stockholders for the three months ended September 30, 2024, was $(18,611,000), compared to $(6,877,000) for the same period in 2023, representing an increase in loss of 170%[18] - Net loss for the nine months ended September 30, 2024, was $9,853,000 compared to a loss of $20,722,000 for the same period in 2023[20] Cash Flow and Liquidity - Cash receipts for Q3 2024 totaled $9.9 million, with cumulative cash receipts of $42.3 million for the first nine months of 2024[1] - On September 30, 2024, XOMA Royalty had cash and cash equivalents of $146.8 million, down from $159.6 million at the end of 2023[13] - Cash and cash equivalents as of September 30, 2024, were $142,050,000, a decrease from $153,290,000 as of December 31, 2023[19] - Cash used in operating activities was $10,845,000, an improvement from $14,231,000 in the prior year[20] - Cash, cash equivalents, and restricted cash at the end of the period totaled $146,816,000, up from $33,472,000 in the previous year[20] Expenses - XOMA Royalty's R&D expenses were $0.8 million in Q3 2024, a notable increase from $25,000 in Q3 2023[7] - General and administrative expenses rose to $8.0 million in Q3 2024, up from $6.4 million in Q3 2023, largely due to costs associated with the Kinnate acquisition[8] - Operating expenses for the three months ended September 30, 2024, totaled $22,837,000, up from $6,617,000 in the same period of 2023, indicating a rise of 245%[18] - Stock-based compensation expense increased to $8,136,000 from $6,450,000 year-over-year[20] Assets and Liabilities - Total assets decreased to $223,340,000 as of September 30, 2024, from $234,301,000 as of December 31, 2023[19] - Total liabilities as of September 30, 2024, were $138,531,000, down from $145,580,000 as of December 31, 2023[19] Acquisitions and Investments - The FDA approved Zevra's MIPLYFFA™ (arimoclomol) for Niemann-Pick disease Type C, adding to XOMA's commercial royalty portfolio[2] - XOMA Royalty acquired a 50% economic interest in TWIST Bioscience's portfolio, which includes over 60 early-stage assets across approximately 30 partners, through a $15 million royalty monetization agreement[4] - The company recognized a gain of $19,316,000 on the acquisition of Kinnate during the nine months ended September 30, 2024[18] - Net cash acquired in the Kinnate acquisition amounted to $18,926,000[20] - Estimated initial fair value of the Exarafenib milestone asset in the Kinnate acquisition was $2,922,000[20] Other Income - The company recorded total other income, net, of $1.9 million in Q3 2024, compared to $0.3 million in Q3 2023, reflecting a $1.3 million increase in investment income[11] - Total interest expense for Q3 2024 was $3.5 million, related to the Blue Owl Loan established in December 2023[10] - Payments of consideration under RPAs, AAAs, and CPPAs totaled $37,000,000, compared to $14,650,000 in the previous year[20] - Net cash provided by investing activities was $8,172,000, a recovery from a cash outflow of $6,222,000 in the prior year[20] - The company recognized a royalty purchase agreement asset impairment of $23,000,000[20]

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milesto ...

XOMA Royalty Corporation (NASDAQ: XOMA ) is a biotechnology royalty aggregator that obtains milestone and royalty rights from investigational and commercial drugs. XOMA's business model is to provide nondilutive funding to biotech companies, allowing them to fund their research without My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens ...

XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%. Financial reports indicate that XOMA achieved a revenue of $11.09 million, net profit of $15.99 million, and earnings per share of $0.88. The gross profit stood at $11.08 million, with a price-to-earnings ratio of -11.85. Within the indust ...

Core Viewpoint - XOMA Royalty Corporation has announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock, reflecting the company's ongoing commitment to return value to its shareholders [1][2]. Group 1: Dividend Announcement - Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive a cash dividend of $0.53906 per share [1]. - Holders of depositary shares representing 1/1000 of a share of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive a cash dividend of $0.52344 per depositary share [2]. - The preferred dividends are scheduled to be paid on or about October 15, 2024, to holders of record as of October 3, 2024 [2]. Group 2: Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, assisting biotech companies in improving human health by acquiring future economic rights associated with therapeutic candidates and commercial assets [3]. - The company has a diverse and expanding portfolio with over 70 assets, defined as rights to receive potential future economics related to the advancement of underlying therapeutic candidates [3]. - The commercial assets in XOMA's portfolio include VABYSMO®, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY®, and DSUVIA®, while other assets are investigational compounds with no established efficacy or safety [4].

Core Insights - XOMA Royalty Corporation will participate in two upcoming investor conferences in September 2024, presenting corporate overviews at both events [1][2]. Group 1: Upcoming Conferences - XOMA will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York, with a presentation scheduled for September 9 at 9:00 AM ET [1]. - The company will also present at the 2024 Cantor Global Healthcare Conference from September 17-19, 2024, in New York, with a presentation on September 17 at 2:30 PM ET [1]. Group 2: Access to Presentations - Presentations can be accessed via the investor relations section of XOMA's website, and replays will be available for 90 days post-event [2]. Group 3: Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotech companies [3]. - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their drug candidates or for general corporate purposes [3]. - XOMA has a growing portfolio of assets, defined as rights to receive potential future economics from therapeutic candidates [3].

XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.69%. A quarter ago, it was expected that this drug developer would post a loss of $0.71 per share when it actually produced a loss of $0.86, delivering a surprise of -21.13%. Over the last four quarters, the company has n ...

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Key Second Quarter Events Partner Event The U.S. Food and Drug Administration (FDA) approved Day One's OJEMDA™ (tovorafenib) for use in patients with pediatric low-grade glioma (pLGG). XOMA Royalty earned a $9.0 million milestone upon the approval and recorded $0.4 million in income resulting from OJEMDA™ sales in the second quarter of 2024. In addition, XOMA Royalty received an ...

Exhibit 99.1 XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities "We continue to build the foundation for accelerating value creation with a disciplined approach to capital deployment," stated Owen Hughes, Chief Executive Officer of XOMA. "In recent months, we've completed the acquisition of Kinnate, acquired economic interests in two commercial assets, as well as in two first-in-class Phase 3 assets, and initiated our first share buyback program on the heels of securing the V ...